Evidence-Based Management of Bullous Pemphigoid

Dermatologic Clinics

Volumn 29, Issue 4, 2011, Pages 613-620

  Daniel, Benjamin S ^a,b   Borradori, Luca ^c   Hall, Russell P ^d   Murrell, Dédée F ^b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF BERN   (Switzerland)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autoimmune bullous disease; Bullous pemhigoid; Systemic corticosteroids; Topical corticosteroids

Indexed keywords

AZATHIOPRINE; CHINESE DRUG; CHLORAMBUCIL; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; IMMUNOGLOBULIN; JINGUI SHENQI; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; TETRACYCLINE; UNCLASSIFIED DRUG;

ACUTE KIDNEY TUBULE NECROSIS; ANEMIA; BULLOUS PEMPHIGOID; CATARACT; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER FUNCTION TEST; MONOTHERAPY; MOOD CHANGE; MORBIDITY; MORTALITY; MYALGIA; MYOPATHY; OSTEOPOROSIS; PEPTIC ULCER; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SEPSIS; SIDE EFFECT; SYSTEMIC THERAPY; TINNITUS;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; AUTOANTIBODIES; AZATHIOPRINE; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; NIACINAMIDE; PEMPHIGOID, BULLOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052906226     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2011.06.003     Document Type: Review

References (59)

1. Bernard P., Vaillant L., Labeille B., et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995, 131(1):48-52.
2. Zillikens D., Wever S., Roth A., et al. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol 1995, 131(8):957-958.
3. Jung M., Kippes W., Messer G., et al. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol 1999, 41(2 Pt 1):266-268.
4. Joly P., Roujeau J.C., Benichou J., et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009, 129(7):1681-1687.
5. Korman N. Bullous pemphigoid. J Am Acad Dermatol 1987, 16(5 Pt 1):907-924.
6. Marazza G., Pham H.C., Scharer L., et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009, 161(4):861-868.
7. Risser J., Lewis K., Weinstock M.A. Mortality of bullous skin disorders from 1979 through 2002 in the United States. Arch Dermatol 2009, 145(9):1005-1008.
8. Taghipour K., Chi C.C., Vincent A., et al. The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. Arch Dermatol 2010, 146(11):1251-1254.
9. Langan S.M., Groves R.W., West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011, 131(3):631-636.
10. Bastuji-Garin S., Joly P., Lemordant P., et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2011, 131(3):637-643.
11. Morel P., Guillaume J.C. Ann Dermatol Venereol 1984, 111(10):925-928. [in French].
12. Dreno B., Sassolas B., Lacour P., et al. Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study. Ann Dermatol Venereol 1993, 120(8):518-521.
13. Hofmann S.C., Kautz O., Hertl M., et al. Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. J Dtsch Dermatol Ges 2009, 7(3):227-233.
14. Chosidow O., Saada V., Diquet B., et al. Correlation between the pretreatment number of blisters and the time to control bullous pemphigoid with prednisone 1 mg/kg/day. Br J Dermatol 1992, 127(2):185-186.
15. Thomas T.P. The complications of systemic corticosteroid therapy in the elderly. A retrospective study. Gerontology 1984, 30(1):60-65.
16. Daniel B.S., Murrell D.F. The actual management of pemphigus. G Ital Dermatol Venereol 2010, 145(5):689-702.
17. Joly P., Roujeau J.C., Benichou J., et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002, 346(5):321-327.
18. Colbert R.L., Allen D.M., Eastwood D., et al. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 2004, 122(5):1091-1095.
19. Parker S.R., Dyson S., Brisman S., et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol 2008, 59(4):582-588.
20. Roujeau J.C., Lok C., Bastuji-Garin S., et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998, 134(4):465-469.
21. Langan S.M., Smeeth L., Hubbard R., et al. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ 2008, 337:a180.
22. Joly P., Benichou J., Saiag P., et al. Response to: mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 2005, 124(3):664-665.
23. Kjellman P., Eriksson H., Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol 2008, 144(5):612-616.
24. Khumalo N.P., Murrell D.F., Wojnarowska F., et al. A systematic review of treatments for bullous pemphigoid. Arch Dermatol 2002, 138(3):385-389.
25. Wojnarowska F., Kirtschig G., Highet A.S., et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002, 147(2):214-221.
26. Kirtschig G., Middleton P., Bennett C., et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010, 10. CD002292.
27. Beissert S., Werfel T., Frieling U., et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007, 143(12):1536-1542.
28. Greaves M.W., Burton J.L., Marks J., et al. Azathioprine in treatment of bullous pemphigoid. Br Med J 1971, 1(5741):144-145.
29. Burton J.L., Harman R.R., Peachey R.D., et al. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J 1978, 2(6146):1190-1191.
30. Guillaume J.C., Vaillant L., Bernard P., et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993, 129(1):49-53.
31. Shiohara J., Yoshida K., Hasegawa J., et al. Tetracycline and niacinamide control bullous pemphigoid but not pemphigus foliaceus when these conditions coexist. J Dermatol 2010, 37(7):657-661.
32. Berk M.A., Lorincz A.L. The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. Arch Dermatol 1986, 122(6):670-674.
33. Kolbach D.N., Remme J.J., Bos W.H., et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol 1995, 133(1):88-90.
34. Fivenson D.P., Breneman D.L., Rosen G.B., et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994, 130(6):753-758.
35. Bara C., Maillard H., Briand N., et al. Methotrexate for bullous pemphigoid: preliminary study. Arch Dermatol 2003, 139(11):1506-1507.
36. Gurcan H.M., Ahmed A.R. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009, 161(4):723-731.
37. Roujeau J.C., Guillaume J.C., Morel P., et al. Plasma exchange in bullous pemphigoid. Lancet 1984, 2(8401):486-488.
38. Thivolet J., Barthelemy H., Rigot-Muller G., et al. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet 1985, 1(8424):334-335.
39. Venning V.A., Millard P.R., Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol 1989, 120(1):83-92.
40. Chu J., Bradley M., Marinkovich M.P. Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch Dermatol 2003, 139(6):813-815.
41. Chave T.A., Mortimer N.J., Shah D.S., et al. Chlorambucil as a steroid-sparing agent in bullous pemphigoid. Br J Dermatol 2004, 151(5):1107-1108.
42. Milligan A., Hutchinson P.E. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol 1990, 22(5 Pt 1):796-801.
43. Czernik A., Bystryn J.C. Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies. Arch Dermatol 2008, 144(5):658-661.
44. Harman K.E., Black M.M. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999, 140(5):865-874.
45. Edhegard K., Ronaghy A., Streilein R.D., et al. Low serum BAFF response and increased IgD B-cell recovery predict clinical flares in bullous pemphigoid (BP) patients treated with rituximab. J Invest Dermatol 2011, 131:s10.
46. Cortes, B Marazza G, Naldi L, et al. Mortality of bullous pemphigoid in Switzerland: a prospective study. Br J Dermatol, May 17, 2011 [online].
47. Bernard P., Reguiai Z., Tancrede-Bohin E., et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol 2009, 145(5):537-542.
48. Downham T.F., Chapel T.A. Bullous pemphigoid: therapy in patients with and without diabetes mellitus. Arch Dermatol 1978, 114(11):1639-1642.
49. Paul M.A., Jorizzo J.L., Fleischer A.B., et al. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1994, 31(4):620-625.
50. Ko M.J., Chu C.Y. Topical tacrolimus therapy for localized bullous pemphigoid. Br J Dermatol 2003, 149(5):1079-1081.
51. Chuh A.A. The application of topical tacrolimus in vesicular pemphigoid. Br J Dermatol 2004, 150(3):622-623.
52. Gurcan H.M., Jeph S., Ahmed A.R. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety. Am J Clin Dermatol 2010, 11(5):315-326.
53. Szabolcs P., Reese M., Yancey K.B., et al. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant 2002, 30(5):327-329.
54. Schmidt E., Seitz C.S., Benoit S., et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007, 156(2):352-356.
55. Reguiai Z., Tchen T., Perceau G., et al. Ann Dermatol Venereol 2009, 136(5):431-434. [in French].
56. Fairley J.A., Baum C.L., Brandt D.S., et al. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009, 123(3):704-705.
57. Schmidt E., Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res 2010, 302(4):241-253.
58. Marker M., Derfler K., Monshi B., et al. Successful immunoapheresis of bullous autoimmune diseases: pemphigus vulgaris and pemphigoid gestationis. J Dtsch Dermatol Ges 2011, 9(1):27-31.
59. Liu B.G., Li Z.Y., Du M. [Effects of jingui shenqi pill combined prednisone on expression of glucocorticoid receptor and its clinical effect in treating bullous pemphigoid patients]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2006, 26(10):881-884. [in Chinese].